GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » PE Ratio

Insulet (Insulet) PE Ratio

: 56.61 (As of Today)
View and export this data going back to 2007. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-18), Insulet's share price is $164.73. Insulet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.91. Therefore, Insulet's PE Ratio for today is 56.61.

Good Sign:

Insulet Corp stock PE Ratio (=56.53) is close to 10-year low of 56.46


The historical rank and industry rank for Insulet's PE Ratio or its related term are showing as below:

PODD' s PE Ratio Range Over the Past 10 Years
Min: 56.36   Med: 698.04   Max: 5169.5
Current: 56.61


During the past 13 years, the highest PE Ratio of Insulet was 5169.50. The lowest was 56.36. And the median was 698.04.


PODD's PE Ratio is ranked worse than
81.37% of 408 companies
in the Medical Devices & Instruments industry
Industry Median: 26.485 vs PODD: 56.61

Insulet's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $1.44. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.91.

As of today (2024-04-18), Insulet's share price is $164.73. Insulet's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $2.83. Therefore, Insulet's PE Ratio without NRI for today is 58.21.

During the past 13 years, Insulet's highest PE Ratio without NRI was 4449.85. The lowest was 57.95. And the median was 590.00.

Insulet's EPS without NRI for the three months ended in Dec. 2023 was $1.40. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $2.83.

During the past 12 months, Insulet's average EPS without NRI Growth Rate was 3828.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 201.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 65.60% per year.

During the past 13 years, Insulet's highest 3-Year average EPS without NRI Growth Rate was 201.80% per year. The lowest was -38.60% per year. And the median was 20.85% per year.

Insulet's EPS (Basic) for the three months ended in Dec. 2023 was $1.48. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.95.


Insulet PE Ratio Historical Data

The historical data trend for Insulet's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 901.05 2,556.30 1,108.63 4,205.57 73.80

Insulet Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,205.57 N/A 323.98 93.27 73.80

Competitive Comparison

For the Medical Devices subindustry, Insulet's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet PE Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's PE Ratio distribution charts can be found below:

* The bar in red indicates where Insulet's PE Ratio falls into.



Insulet PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Insulet's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=164.73/2.910
=56.61

Insulet's Share Price of today is $164.73.
Insulet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.91.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Insulet  (NAS:PODD) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Insulet PE Ratio Related Terms

Thank you for viewing the detailed overview of Insulet's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet (Insulet) Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Executives
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Shacey Petrovic officer: CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Prem Singh officer: SVP, Global Operations C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
James Hollingshead director C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan officer: EVP, CFO C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Mark N Field officer: SVP & Chief Technology Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea officer: SVP, Chief HR Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue director 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin officer: SVP, Reg, Quality & Compliance C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche officer: SVP, Global Manufacturing C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bret Christensen officer: SVP and CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Michael P Spears officer: SVP, Quality and Regulatory C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David A Lemoine director C/O THE L S STARRETT COMPANY, 121 CRESCENT STREET, ATHOL MA 01331
Sally Crawford director C/O HOLOGIC, INC., BEDFORD MA 01730

Insulet (Insulet) Headlines

From GuruFocus

Insulet Corp at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Insulet Corp at Nasdaq Investor Conference Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Insulet Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2021 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Insulet Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024